Shilpa Medicare Limited — Important, 04-07-2025: General Updates

Shilpa Medicare’s 100% subsidiary, Shilpa Pharma Lifesciences Limited Unit-1, has cleared the Brazilian ANVISA GMP audit with no critical or major findings. Only minor procedural observations were noted, which the company will address through corrective actions. This regulatory clearance supports the subsidiary’s export capabilities and strengthens Shilpa’s position in the Brazilian pharmaceutical market.